Drugs / Genetically Engineered Hematopoietic Stem Progenitor Cells
Genetically Engineered Hematopoietic Stem Progenitor Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01331018 | Feb 2012 → Feb 2024 | Fanconi anemia | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04871607 Background | Nov 2021 → Oct 2029 expected | Hodgkins lymphoma | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genetically Engineered Hematopoietic Stem Progenitor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871607 ↗ |
| Action | Restore | “corrected in the laboratory by introduction of the normal gene” NCT01331018 ↗ |
| Modality | Cell therapy | “genetically modified hematopoietic progenitor cell therapy” NCT01331018 ↗ |
| Route | Other | “Given via infusion” NCT04871607 ↗ |